Tenaya Therapeutics (TNYA) Competitors $0.72 +0.03 (+4.06%) As of 01:05 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TNYA vs. FULC, CKPT, AQST, CYRX, CMPX, ARCT, ALT, BNTC, ATXS, and TERNShould you be buying Tenaya Therapeutics stock or one of its competitors? The main competitors of Tenaya Therapeutics include Fulcrum Therapeutics (FULC), Checkpoint Therapeutics (CKPT), Aquestive Therapeutics (AQST), CryoPort (CYRX), Compass Therapeutics (CMPX), Arcturus Therapeutics (ARCT), Altimmune (ALT), Benitec Biopharma (BNTC), Astria Therapeutics (ATXS), and Terns Pharmaceuticals (TERN). These companies are all part of the "pharmaceutical products" industry. Tenaya Therapeutics vs. Its Competitors Fulcrum Therapeutics Checkpoint Therapeutics Aquestive Therapeutics CryoPort Compass Therapeutics Arcturus Therapeutics Altimmune Benitec Biopharma Astria Therapeutics Terns Pharmaceuticals Fulcrum Therapeutics (NASDAQ:FULC) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership. Do analysts recommend FULC or TNYA? Fulcrum Therapeutics presently has a consensus price target of $6.29, suggesting a potential downside of 18.99%. Tenaya Therapeutics has a consensus price target of $6.25, suggesting a potential upside of 770.47%. Given Tenaya Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tenaya Therapeutics is more favorable than Fulcrum Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fulcrum Therapeutics 1 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.50Tenaya Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is FULC or TNYA more profitable? Fulcrum Therapeutics' return on equity of -0.20% beat Tenaya Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Fulcrum TherapeuticsN/A -0.20% -0.19% Tenaya Therapeutics N/A -92.20%-74.53% Do institutionals & insiders hold more shares of FULC or TNYA? 89.8% of Fulcrum Therapeutics shares are owned by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are owned by institutional investors. 7.0% of Fulcrum Therapeutics shares are owned by insiders. Comparatively, 48.7% of Tenaya Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media favor FULC or TNYA? In the previous week, Fulcrum Therapeutics had 1 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 3 mentions for Fulcrum Therapeutics and 2 mentions for Tenaya Therapeutics. Fulcrum Therapeutics' average media sentiment score of 0.78 beat Tenaya Therapeutics' score of 0.47 indicating that Fulcrum Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulcrum Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tenaya Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger earnings and valuation, FULC or TNYA? Fulcrum Therapeutics has higher revenue and earnings than Tenaya Therapeutics. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFulcrum Therapeutics$80M5.24-$9.73M-$0.07-110.84Tenaya TherapeuticsN/AN/A-$111.13M-$1.16-0.62 Which has more volatility and risk, FULC or TNYA? Fulcrum Therapeutics has a beta of 2.37, suggesting that its stock price is 137% more volatile than the S&P 500. Comparatively, Tenaya Therapeutics has a beta of 3, suggesting that its stock price is 200% more volatile than the S&P 500. SummaryFulcrum Therapeutics beats Tenaya Therapeutics on 8 of the 15 factors compared between the two stocks. Get Tenaya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TNYA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TNYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TNYA vs. The Competition Export to ExcelMetricTenaya TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$116.63M$2.92B$5.56B$9.30BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-0.6220.3528.6119.64Price / SalesN/A304.32437.49188.30Price / CashN/A43.1536.0257.93Price / Book0.677.718.185.63Net Income-$111.13M-$55.11M$3.23B$257.73M7 Day Performance6.99%0.68%-0.25%0.07%1 Month Performance15.38%8.22%5.40%8.32%1 Year Performance-81.11%-2.64%26.35%13.78% Tenaya Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TNYATenaya Therapeutics3.4057 of 5 stars$0.72+4.1%$6.25+770.5%-80.4%$116.63MN/A-0.62110FULCFulcrum Therapeutics0.6096 of 5 stars$7.02+1.4%$6.29-10.5%-7.2%$378.94M$80M-100.27100CKPTCheckpoint Therapeutics0.4539 of 5 stars$4.26flat$4.33+1.7%N/A$370.71M$41K-2.3210AQSTAquestive Therapeutics1.945 of 5 stars$3.70-0.5%$10.14+174.1%+45.1%$367.52M$57.56M-6.27160CYRXCryoPort2.1487 of 5 stars$7.29-4.8%$11.00+50.9%-1.3%$365.52M$228.38M-3.121,186CMPXCompass Therapeutics3.0338 of 5 stars$2.64-5.0%$12.67+379.8%+195.0%$365.06M$850K-6.4420Positive NewsARCTArcturus Therapeutics1.9772 of 5 stars$13.36-3.0%$54.00+304.2%-43.8%$362.32M$152.31M-5.28180ALTAltimmune2.1879 of 5 stars$4.43-6.9%$19.00+328.9%-47.1%$359.32M$20K-3.5250BNTCBenitec Biopharma1.4529 of 5 stars$13.49+2.4%$23.83+76.7%+22.0%$354.11M$80K-8.9320High Trading VolumeATXSAstria Therapeutics1.5983 of 5 stars$6.20+6.7%$30.00+383.9%-46.7%$349.87MN/A-3.3230TERNTerns Pharmaceuticals3.8266 of 5 stars$4.00-7.4%$15.63+290.6%-49.4%$349.35MN/A-3.6740 Related Companies and Tools Related Companies Fulcrum Therapeutics Competitors Checkpoint Therapeutics Competitors Aquestive Therapeutics Competitors CryoPort Competitors Compass Therapeutics Competitors Arcturus Therapeutics Competitors Altimmune Competitors Benitec Biopharma Competitors Astria Therapeutics Competitors Terns Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TNYA) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredAll New Social Security Numbers coming July 23?To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenaya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenaya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TNYA Stock Alerts